ARQ-087

Derazantinib (ARQ-087) is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.


Cat. No.: EX-A1717	Purity: >98%

	Chemical structure of ARQ-087

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	399	in_stock
500mg	650	in_stock
1g	1030	in_stock
5g	3859	inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Derazantinib
CAS No.	1234356-69-4
Purity	>98%
Formula	C29H29FN4O
Mol Weight	468.5652
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. [2]. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66
CoA	CoA of ARQ-087

Smiles:	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C4=CC=CC=C4C3=N2)=CC=C1


		Search